Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01202279 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI
A Phase 4 study, sponsored by Reckitt Benckiser.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,179
- Enrollment target
NCT01202279 is a Phase 4 study that has completed, run by Reckitt Benckiser. The registered enrollment target is 1,179 participants.
The verdict
NCT01202279, a Phase 4 study, has completed, sponsored by Reckitt Benckiser.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,179 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with Mucinex D lowers the use of antibiotics in the treatment of upper respiratory infection when compared to placebo
Interventions
- DEVICE Placebo
- DRUG Guaifenesin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,179 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01202279
The ClinicalTrials.gov registry entry for NCT01202279 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reckitt Benckiser, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01202279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01202279 about?
NCT01202279 is a clinical study titled "Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI". The purpose of this study is to determine if treatment with Mucinex D lowers the use of antibiotics in the treatment of upper respiratory infection when compared to placebo
What is the current status of trial NCT01202279?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,179 participants. The study started on 2009-10. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01202279?
The interventions under investigation include: Placebo (DEVICE), Guaifenesin (DRUG).
Who is sponsoring clinical trial NCT01202279?
This trial is sponsored by Reckitt Benckiser, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.